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HumanIn the acute phase of leptospirosis, the diagnosis can be established with high sensitivity by testing blood and
urine samples with polymerase chain reaction (PCR). However, only few real-time PCR assays have been val-
idated for diagnostic use.
The diagnostic accuracy of a novel TaqMan® PCR (LipL32 real-time PCR) targeting the lipl32 gene (or hap-1) and
a previously described TaqMan® PCR (16S real-time PCR) targeting the rrs gene coding for 16S rRNA was eval-
uated when applied to both urine and blood specimens from humans suspected of leptospirosis.
Applied to at least two blood cultures LipL32 real-time PCR had a sensitivity of 86%, and a speciﬁcity of 100%;
and 16S real-time PCR had a sensitivity of 100%, and a speciﬁcity of 97%. Applied to urine samples, patients
that were positive by the reference methods were also positive by both real-time PCR assays (n=4). For
LipL32 real-time PCR the speciﬁcity was 100%, while for 16S real-time PCR it was only 91.5% due to unexpected
cross-reactions with other bacteria. The analytical sensitivity was close to the theoretical limit-of-detection for
both assays detecting all described human pathogenic species.
We report a speciﬁc real-time PCR assay for detection of Leptospira, i.e., LipL32 real-time PCR that has been
validated for diagnostic application in both urine and blood specimens from humans. We further show that a
previously described 16S real-time PCR no longer can be recommended for diagnostic use due to a low
speciﬁcity.
© 2012 Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
Leptospira species is the causative agent of leptospirosis, a disease
that, despite being among the world's most widespread zoonoses, also
is one of themost neglected diseases. Carrier animals excrete the bacte-
ria in large numbers with urine, and transmission to humans occurs
mainly through contactwithwater or crops contaminatedwith infected
urine (Levett, 2001). Signs and symptoms of the disease range from
mild ﬂu-like symptoms to severe sepsis with multi-organ failure
(Bharti et al., 2003a; Levett, 2001). In humans, the disease is endemic
mainly in developing countries in the tropics where outbreaks occur
frequently after heavy rainfalls (Bharti et al., 2003a). Travelers to
these countries may be exposed to Leptospira during activities in fresh-
water for example by engaging in white-water-rafting. Earlier, it was
shown that leptospirosis is a relatively common cause of fever in
Swedish travelers returning from the tropics (Askling et al., 2009). Diag-
nosis can only be obtained by speciﬁc tests, limited in availability to a45 32683147.
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NC-ND license.few specialist laboratories. Since leptospirosis is considered a rare dis-
ease in most developed countries, the diagnosis is likely to be missed,
and the few diagnosed cases likely represent an under-estimate. Lepto-
spirosis is notiﬁable in many countries, and a deﬁnite diagnosis may
help in identifying outbreaks and risk factors, valuable in a public health
perspective (Sejvar et al., 2003).
The gold standard for diagnosing leptospirosis is detection of spe-
ciﬁc antibodies against Leptospira spp. in a convalescence serum sam-
ple by the microscopic agglutination test (MAT). MAT is often not
positive until after the seventh day of disease. Leptospirosis can also
be diagnosed by isolation of the bacterium. Nevertheless, culture of
Leptospira spp. requires special growth media, is slow, and in most
clinical settings it has a very low sensitivity. Detection of DNA in clin-
ical samples is increasingly used, and PCR assays have been developed
for leptospirosis. In the acute phase of the disease, Leptospira spp. is
present in high numbers in multiple body ﬂuids including blood, spi-
nal ﬂuid and urine. Thus, a high sensitivity for PCR assays can be
obtained when samples are taken before initiation of antimicrobial
therapy (Ahmed et al., 2009; Slack et al., 2007; Villumsen et al., 2010).
In a hospital setting, most cases suspected of severe leptospirosis
will be treated empirically with broad-range antibiotics effective
against most bacteria including Leptospira spp., before a deﬁnite diag-
nosis is established. However, by obtaining an early diagnosis, the
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such as benzyl penicillin, thereby reducing the adverse effects, the
economical, and the ecological cost of the initial broad-spectrum
treatment. Furthermore, an early deﬁnite diagnosis allows the clini-
cian to optimize the supportive treatment and give a more precise es-
timate of the cause and prognosis of the disease (Bharti et al., 2003b).
For these purposes, tests with high sensitivity and speciﬁcity are
needed.
In diagnostic laboratories, real-time PCRs are increasingly being
used instead of conventional PCR. These techniques are faster, require
less laboratory personnel and are performed in a closed system, thereby
reducing the risk of DNA cross-contamination. Potentially, they further
allowquantiﬁcation of the targeted organismas a quantitative real-time
PCR (qPCR). A disadvantage of real-time-PCR is that the ampliﬁed DNA
sequence is often too short to allow conﬁrmation by sequencing of the
ampliﬁed DNA product, if there is disagreement between the clinical
and laboratory ﬁndings. Consequently, a thorough validation of the
assay should be undertaken and, preferably, all ﬁndings should be con-
ﬁrmed by an independent PCR assay targeting another relevant gene.
Despite the several real-time-PCR assays that have been described for
diagnosis of leptospirosis (Ahmed et al., 2009; Levett et al., 2005;
Merien et al., 2005a; Palaniappan et al., 2005; Roczek et al., 2008;
Rojas et al., 2010; Slack et al., 2007; Smythe et al., 2002; Stoddard et
al., 2009), only a few of these assays have been validated for diagnostic
use on blood samples (Ahmed et al., 2009; Slack et al., 2007; Smythe et
al., 2002) and to our knowledge, only one real-time PCR (Rojas et al.,
2010) has been validated for diagnostic use in canine urine samples
and none have been validated for use with human urine samples.
The aim of this studywas to compare the diagnostic accuracy of two
TaqMan® PCR assays; a novel assay (LipL32 real-time PCR) targeting
the lipl32 gene (or hap-1) and a previously described assay (16S
real-time PCR) targeting the rrs gene coding for 16S rRNA (Smythe et
al., 2002). The sensitivity and speciﬁcity of both assays were deter-
mined, when they were applied to bacterial isolates and clinical blood
and urine samples from human patients. When appropriate, the results
were related to convalescence serology or sequencing of the ampliﬁed
PCR product as a reference standard. We point out the importance of
performing a detailed validationwith all relevant specimens of diagnos-
tic assays used in the clinical laboratories.
2. Materials and methods
2.1. Evaluation on clinical samples
2.1.1. Samples from patients suspected of leptospirosis
Statens Serum Institut (SSI) is the only laboratory performing rou-
tine diagnostic testing for Leptospira spp. from humans in Denmark. In
the period from January 2005 to June 2008, all blood cultures (BCs)
and urine samples submitted for diagnostic purposes were either in-
oculated in Difco™ Leptospira medium — EMJH in order to isolate
Leptospira and/or subjected to dark-ﬁeld microscopy (urine samples
only). The remainder of the BCs and urines were stored at −20 °C.
When diagnostic follow-up was completed, the patient identiﬁca-
tions were removed from the samples which were linked to the re-
sults of corresponding MAT, culture and dark-ﬁeld microscopy by a
unique, anonymous code. For some patients, there was information
available that antibiotic therapy had been initiated before the samples
were taken. These samples were subsequently excluded from the
study. The BCs included in this study have previously been used for
evaluation of DNA extraction methods (Cerqueira and Picardeau,
2009; Villumsen et al., 2010).
2.1.1.1. Blood culture specimens from patients suspected of leptospirosis.
Ninety-six blood cultures (BACTEC™ aerobic Plus n=20; BACTEC™
anaerobic Plus n=21; BACTEC™ Paed Plus n=2; BacT/ALERT® SA
n=23, BacT/ALERT® SN n=21; BacT/ALERT® FA n=8; BacT/ALERT®FN n=1) were obtained from 36 patients suspected of leptospirosis
(4 (11%) females and 32 (89%) males; median age 38 years; range
2 years to 78 years). Twenty-nine of the 36 patients were tested for an-
tibodies against Leptospira spp. at some point during the acute phase of
the disease. Of the 29 patients, 11 were tested for antibodies at least
7 days after debut of the symptoms. Of these, seven patients were pos-
itive for antibodies against Leptospira. None, of the remaining 18 pa-
tients were positive.
2.1.2. Samples from control patients
Urine samples submitted to Statens Serum Institut for PCR analysis for
Chlamydia trachomatis and/or Mycoplasma genitalium and spinal ﬂuid
submitted for PCR analysis for Neisseria meningitidis and Streptococcus
pneumoniae or Toxoplasma gondii were used as control samples. When
diagnostic follow-up was completed, the patient identiﬁcations were re-
moved from the samples which were linked to the results of the
requested tests by a unique, anonymous code. All clinical samples were
included in the “Leptospira: PCR diagnostics” material collection (Danish
Data Protection Agency: journal number 2010-41-4862).
2.2. Ethical considerations
Exemption for review by the ethical committee system and for
obtaining informed consent was obtained from the Committee on
Biomedical Research Ethics for Capital Region (protocol number:
H-1-2010-FSP-20) in accordance with Danish law on quality develop-
ment projects.
2.3. Evaluation on cultured strains
2.3.1. Bacterial isolates
Twenty-nine Leptospira spp. strains were included in the study
(Table 1). All strains were obtained from KIT Biomedical Research,
WHO/FAO Collaborating Centre for Reference and Research on Lepto-
spirosis, the Netherlands. The strains consisted of 16 different deﬁned
or candidate genomospecies that are often classiﬁed into either patho-
genic, intermediate pathogenic or saprophytic species based on phylo-
genetic clustering and to some extent animal studies and clinical
ﬁndings (Ahmed et al., 2009; Stoddard et al., 2009). Further, ﬁve phylo-
genetically closely related bacterial species were included in order to
asses for unexpected cross-reactivity: Treponema pallidum strain Nichol,
Treponema phagedenis biotype Reiter, Borrelia burgdorferi strain DK1,
Turneriella parva strain H, Leptonema illini strain 3055.
Strains of Leptospira spp. listed in Table 1 and marked with 1 were
cultured under aerobic conditions in Difco™ Leptospira medium —
EMJH until late log-phase. T. pallidum was grown in rabbit testicles
(Oryctolagus cuniculus), Crl:KBL(NZW) (Charles River Laboratories,
Sulzfeld, Germany), T. phagedenis in thioglycollate medium (SSI Diag-
nostics, Hillerød, Denmark) under anaerobic conditions. B. burgdorferi
was cultured in BSK medium (SSI Diagnostics) under aerobic condi-
tions. DNA from all cultures was extracted as described under DNA ex-
traction methods.
Strains of Leptospira in Table 1 marked with 2 and T. parva strain H,
L. illini strain 3055 were provided as puriﬁed DNA extracts from
whole cell bacteria by KIT Biomedical Research. The DNA content of all
extracts of Leptospira spp. strains was determined using Qubit™ Fluo-
rometer (Invitrogen, Naerum, Denmark) with Quant-iT™ DNA Assay
Kits (Invitrogen) as described by the manufacturer. The measured
DNA content was further converted into GEq using an average genome
size of 4.6 megabases.
The puriﬁed genomic DNA of all Leptospira spp. strains was diluted
by ten-fold dilutions in a DNA-buffer consisting of Tris–EDTA buffer
(10 mM Tris pH 8.0, 1 mM EDTA [Sigma-Aldrich]) with 1 μg/ml calf
thymus DNA (Sigma-Aldrich) until the concentration in each dilution
was below 2×106 genome equivalents of Leptospira (GEq)/μl. A rough
estimate of the sensitivity was determined by testing the 10-fold
Table 1
Estimated limit of detection for Leptospira spp. strains used in the evaluation.
Genomospecies Serovar Strain Virulence Limit of detection/ (GEq/5 μl)
16S qPCR LipL32 qPCR
Leptospira alexanderi2 Mengla A 85 Pathogenic b100 b100
Leptospira borgpetersenii1 Sejroe M84 Pathogenic b10 b10
Leptospira borgpetersenii1 Ballum Castellon 3 Pathogenic b10 b10
Leptospira borgpetersenii1 Tarassovi Perepelitsin Pathogenic b10 b100
Leptospira genomospecies 12 Pingchang 80–412 Pathogenic b100 ND
Leptospira interrogans1 Autumnalis Akiyami A Pathogenic b100 b100
Leptospira interrogans1 Australis Ballico Pathogenic b10 b10
Leptospira interrogans1 Hardjo Hardjoprajitno Pathogenic b10 b10
Leptospira interrogans1 Hebdomadis Hebdomadis Pathogenic b10 b100
Leptospira interrogans1 Canicola Hond Utrecht IV Pathogenic b10 b10
Leptospira interrogans1 Copenhageni M20 Pathogenic b100 b100
Leptospira interrogans1 Pomona Pomona Pathogenic b10 b10
Leptospira interrogans1 Icterohaemorragiae RGA Pathogenic b10 b10
Leptospira interrogans1 Pyrogenes Salinem Pathogenic b10 b10
Leptospira interrogans1 Bataviae Swart Pathogenic b10 b10
Leptospira interrogans1 Sejroe 3705 Pathogenic b10 b100
Leptospira kirschneri1 Grippotyphosa Moskva V Pathogenic b10 b10
Leptospira kirschneri 1 Cynopteri 3522 C Pathogenic b10 b100
Leptospira noguchii1 Panama CZ 214 Pathogenic b10 b100
Leptospira santarosai2 Shermani 1342 K Pathogenic b100 b100
Leptospira weilii2 Celledoni Celledoni Pathogenic b100 b100
Leptospira genomospecies 32 Holland WaZ Holland Pathogenic >100.000 ND
Leptospira broomii1 L065 Intermediate b10 b10
Leptospira fainei2 Hurstbridge BUT 6 Intermediate b100 ND
Leptospira indai2 Lyme Lyme 10 Intermediate b10 ND
Leptospira biﬂexa1 Semaranga Patoc I Saprophytic ND ND
Leptospira genomospecies 52 SaoPaulo Sao Paulo Saprophytic ND ND
Leptospira meyeri2 Ranarum ICF Saprophytic b100 ND
Leptospira wolbachi2 Codice CDC Saprophytic ND ND
Limit of detection determined by duplicate testing of ten-fold dilutions of puriﬁed DNA of Leptospira spp. The tested strains of Leptospira spp. are divided into pathogenic, interme-
diate pathogenic (intermediate) and saprofytic strains based phylogenetic clustering and known virulence.
GEq=genome equivalent of Leptospira; ND=not detected.
1 DNA extracted from cultivated strains; split.
2 DNA obtained from reference laboratory.
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testing in both LipL32 real-time PCR and 16S real-time PCR.
2.3.2. Determining the limit of detection
Puriﬁed genomic DNA from Leptospira interrogans serovar
Icterohaemorragiae strain RGA was diluted in ten-fold serial dilutions
in DNA buffer to a concentration of 7 GEq/5 μl. From this stage, further
two-fold dilution was prepared until a concentrationb1 GEq/5 μl.
Dilutions with a concentration ranging from 7.0×101 GEq/5 μl to
7.0×105 GEq/5 μl were tested in duplicate by both real-time PCR assays
and dilutions in the range of 0.875 GEq/5 μl to 7 GEq/5 μl were tested in
10 replicates. Limit of detection (LOD) for each TaqMan® real-time PCR
assaywasdeﬁned as the concentration of GEq/assay (5 μl)where 95% of
all tested samples were positive (Hughes and Totten, 2003). For each
real-time PCR assay, the LOD was estimated by logistic regression anal-
ysis as described under statistical analysis.
2.4. Development of new TaqMan® PCR targeting LipL32
In order to design primers and a corresponding probe for the
TaqMan® system targeting the lipl32 gene, also designated hap-1, a
major outer-membrane lipoprotein highly conserved among patho-
genic Leptospira spp. (Haake et al., 2000a), sequences of the lipl32
gene from 82 isolates (Appendix A) were retrieved from GenBank
and aligned using the ClustalW algorithm in the program MegAlign
vers 5.03 in DNAStar. From this alignment a consensus sequence was
obtained. The consensus sequencewas used as template in the program
Primer-Express® version 3.0 (ABI, Applied Biosystems, Foster City, CA)
to generate suggestions for probes and primers suitable for a TaqMan®
PCR assay. Standard conditions for TaqMan® MGB Quantiﬁcation were
used in the calculation. Subsequently, the suggested primers- andprobe-sequences were manually compared to the individual LipL32 se-
quences in order to avoid mismatches. Using this approach the forward
primer, LipL32F: 5′-AGA GGT CTT TAC AGA ATT TCT TTC ACT ACC T-3′,
reverse primer, LipL32R: 5′-TGG GAA AAG CAG ACC AAC AGA-3′
ﬂanking an 87 base pair fragment of the consensus sequence of the
lipl32 gene. The probe was labeled with 6-carboxy-ﬂuoroescein (FAM)
and a Minor Groove Binder (MGB) moiety was used as quencher and
to increase the melting temperature, allowing the use of a shorter
probe that did not span mismatches in the consensus sequence. The
probe designated LipL32-P: 5′-FAM-AAG TGA AAG GAT CTT TCG TTG
C-MGB-3′ was selected. This assay will be referred to as “LipL32
real-time PCR”. Primers and probes were evaluated by BLAST search
for possible cross-reactions.
2.5. Primers and probe targeting the gene coding for 16S rRNA
A previously published (Smythe et al., 2002) and appraised (Bharti
et al., 2003a) TaqMan® PCR assay targeting the rrs gene coding for
16S rRNA was used to compare the performance of the new assay.
The probe was labeled with FAM and quenched with Black Hole
Quencher. This assay will be referred to as “16S real-time PCR”.
2.6. Real-time PCR assays
The master mix was prepared according to an in-house protocol
as previously described (Jensen et al., 2004b) and included an inter-
nal ampliﬁcation control (IAC) in order to assess inhibition or sub-
optimal reaction conditions. The principle of the IAC has previously
been described (Jensen et al., 2003). The total reaction volume for all
PCR assays was 50 μl and included 5 μl of template DNA. Ultrapure
water (Invitrogen, CA) was used as a no-template control (NTC). Seven
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idation experiments.
Samples were ampliﬁed in an Applied Biosystems 7500 quantitative
PCR Systemusing 50 cycles of 15 s denaturation at 94 °C and 60 s com-
bined annealing and extension at 60 °C. For all assays, standards con-
sisting of 10-fold dilutions of puriﬁed genomic DNA of L. interrogans
serovar Icterohaemorrhagiae strain M695 were included (Villumsen
et al., 2010). Standards ranging in concentrations from approximately
100,000 GEq to 100 GEq/assay were used to calculate the standard
curve, while the standard with 10 GEq/assay was used as a LOD control
included in duplicate in each PCR. Only ampliﬁcation curves with expo-
nential rise in the signal and with an estimated quantity of ≥1 GEq
were considered as positive.
2.7. DNA extraction methods
2.7.1. Blood cultures
The BCs were subjected to an improved benzyl alcohol and column
based DNA extraction protocol as previously described (Villumsen et
al., 2010). By this method the DNA from the blood culture is diluted to
49 to 66% of the input concentration.
2.7.2. Urine
All urine samples were subjected to a Chelex® 100-based DNA ex-
traction method as previously described (Jensen et al., 2004a). By this
method, DNA from 1.8 ml urine was concentrated by centrifugation
and the DNA released by boiling in a ﬁnal volume of 300 μl Chelex®
100 slurry in TE-buffer, thus resulting in a 6 fold concentration of the
DNA from intact bacteria.
2.7.3. Bacterial isolates
DNA from the cultured bacteria was extracted using the DNeasy
Blood & Tissue Kit (QIAGEN, Hilden, Germany) according to the man-
ufacturer's instructions using the protocol for animal blood or cells.
2.8. Reference methods
2.8.1. Serological analysis
Where requested by the clinicians, corresponding serum samples
were tested for antibodies against Leptospira spp. by an ISO 17025
accredited microscopic agglutination test (MAT) conducted as previ-
ously described (Villumsen et al., 2010).When only a single serum sam-
ple was available for MAT, the test was considered positive if the titer
(reciprocal dilution) was above 1000 and inconclusive if the titer was
within the range of 100–300. When two serum samples were available
and these were obtained up to 4 weeks apart during the acute phase of
the disease, the test was considered positive when a sero-conversion
from no reaction to a titer of at least 100 or if a two-fold rise in titer
was observed. MAT performed on a convalescence serum sample is a
recognized reference method in the diagnosis of leptospirosis (Levett,
2001). Samples thatwere real-time PCR and sero-negativewere consid-
ered as true negative.
2.8.2. Cloning and sequencing
In patients that were MAT negative and real-time PCR positive,
sequencing of the amplicons was used as a reference standard. The
length of the inter-primer sequence was only 55 bp for the 16S
real-time PCR and 35 bp for the LipL32 real-time PCR allowing only to
rule-out certain species based on mismatches. In order to obtain the lon-
gest possible DNA sequence for identiﬁcation, only 16S-amplicons were
sequenced. Selected 16S-amplicons were precipitated with ethanol,
re-suspended in TE buffer and cloned in PCR®2.1-TOPO vector (Invi-
trogen) using TOP10 cells as recommended by the manufacturer. Inserts
from selected clones were PCR ampliﬁed using the m13 forward
and reverse primers, and the amplicons were sequenced using the
BigDye Terminator v 3.1 kit and an ABI3130xl sequencer (AppliedBiosystems). Sequences were compared to GenBank using BLAST
search. The results of the real-time PCR were considered as true pos-
itive if the inter-primer sequence of the amplicons had less than a
two base-pair difference with that of Leptospira spp. and if both of
the real-time PCR assays were positive, while it was considered as
false-positive if there were 2 or more base pairs in difference.
2.9. Statistical analysis
A logistic regressionmodel was ﬁtted to data using the PROC logistic
(SAS 9.1; SAS Institute, USA) to analyze the effect of the concentration of
Leptospira GEq in the template on the outcome positive/negative of the
real-time PCR test and the LOD was determined graphically. To assess
for removal of inhibitors of the PCR for each PCR plate, the Ct-values
of the IAC in assays that were negative for Leptospira were compared
to the Ct-values of the NTC by a two-sample t-test of the mean.
3. Results
3.1. Evaluation on clinical samples
3.1.1. Blood culture specimens from patients suspected of leptospirosis
Results of the analysis by the two real-time PCRs and the
corresponding serological tests are shown in Table 2. The results of
the 16S real-time PCR applied to the BCs have previously been used
for evaluation of DNA extractions methods (Villumsen et al., 2010).
One seropositive and one seronegative patient were found to be nega-
tive by the LipL32 real-time PCR: in two BCs both were positive by the
16S real-time PCR assay in one of the BCs (although close to the LOD).
In the seronegative patient, the sequence of the 16S-amplicon matched
only uncultured bacteria when a BLAST search was performed. Further,
the sequence had only one base pair mismatch with the probe, indicat-
ing that this was a false-positive reaction. In the seropositive patient,
the tested samples were taken on the 10th day of disease. A total of
20 BCs were obtained from the 7 seropositive patients. 16 of these BCs
were positive by 16S real-time PCR and 15 by LipL32 real-time PCR.
The estimated recovery was close to LOD in all of these last three BCs.
All negative controls (NTCs) were negative for Leptospira while the
IAC was present in all samples that were negative for Leptospira. In
one of the seven patients that were true-positive by both PCR assays,
EMJH-subculture of one of the BCs (BACTEC™ aerobic Plus) was found
positive for Leptospira borgpetersenii senso stricto.
3.1.2. Urine from patients suspected of leptospirosis
Urine samples, one from each of 60 patients were received for rou-
tine analysis for Leptospira spp. Two seropositive patients were subse-
quently excluded from the study, since there was clinical information
available that the urine samples had been taken 1 and 4 days after the
patients had started treatment with benzyl penicillin. One of these
two patients was positive by the 16S real-time PCR close to the LOD in
one of two replicates while both patients were negative in duplicate
by the LipL32 real-time PCR. Of the remaining 58 patients (median
age 41 years, range 4 years to 74 years; female, n=12, male=n=
46), 16 were tested by dark ﬁeld microscopy only, 7 by culture only,
and 35 by both culture and dark ﬁeld microscopy. None of the samples
were positive for Leptospira spp. with either dark ﬁeld microscopy or
culture. Data for time of sampling were available from 50 patients.
The median time from sampling to test was 1 day; range of 1 h to
7 days. Only 7 samples were received and examined within 3 h from
sampling and of these, none were positive by any of the two real-time
PCR assays.
Results of the analysis by the two real-time PCRs and the cor-
responding serological tests are shown in Table 2. In four patients, the
urine samples were taken within hours after admission to hospital
and were positive by both real-time PCR assays. In three of these pa-
tients, the diagnosis was conﬁrmed by serology. In the PCR-positive
Table 2
Outcome of TaqMan® PCR and serology from patients suspected of Leptospirosis and controls.
Study group Serum samples Urine samples Blood cultures
Serology (MAT) n 16S qPCR LipL32 qPCR n 16S qPCR LipL32 qPCR
Positive Negative Positive Negative Positive Negative Positive Negative
Patients No serum 4 0 4 0 4 8 0 8 0 8
Positive 3 3 0 3 0 7 7 0 6 1
Inconclusive 3 0 3 0 3 0 0 0 0 0
Negative 48 1 47 1 47 21 1a 20 0 21
Total 58 4 54 4 54 36 8 28 6 30
Controls No serum 99 13a 86 0 99
16S qPCR, a previously described TaqMan® PCR targeting the rrs gene coding for 16S rRNA. LipL32 qPCR, a novel quantitative PCR targeting the lipl32 gene. MAT = microscopic
agglutination test.
a False positive results.
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sequenced and had 100% homologywith that of Leptospira spp. Theme-
dian bacterial load of Leptospira in the four PCT positive urine samples
was 23 GEq (range 12 GEq to 2103 GEq). Ampliﬁcation of the IAC was
noted in all of the real-time PCR negative samples. When these samples
were tested by the LipL32 real-time PCR, the mean observed cycle
threshold (Ct) value of the IAC was, 0.3 Ct (0.1–0.5 Ct; pb0.01) and
0.3 Ct (0.1–0.5 Ct; p=0.04) higher than the mean Ct value observed
when the corresponding NTCs were tested. This indicates that there
was a very slight but negligible inhibition of the qPCR assays when
urine samples were tested as the difference was less than 1 cycle.
In 54 of the 58 patients a corresponding serumsamplewas tested for
antibodies against Leptospira spp. In 22 of these patients, the last serum
samplewas collected at least 7 days after onset of the symptoms;medi-
an time of sampling was 17 days; range of 7 days to 119 days. Two of
the patients were both seropositive and PCR-positive. In the remaining
32 of 54 patients, only one serum sample was available and this was
most often taken on the same date as the urine sample.
3.1.3. Urine from control patients
A urine sample was received from each of 99 patients (median
age 25 years; range 3 years to 65 years; male n=64; female n=
35) for PCR analysis for C. trachomatis alone (n=37), M. genitalium
alone (n=2) or both C. trachomatis and M. genitalium (n=60). All
of the 99 urine samples were negative by the LipL32 real-time PCR
and the IAC was ampliﬁed in all of these real-time PCR assays.
Urine samples from 13 patients (females n=9, males n=4; median
age 20 years, range 3 to 46 years) were positive by the 16S real-time
PCR in duplicate testing. Themedian quantitywas approximately 8 GEq
of Leptospira spp. (range 1 GEq to 254 GEq). In addition, 6 control pa-
tientswere positive in one of the two duplicates and in a further 23 con-
trol patients, a weak ampliﬁcation below the LOD was detected. All
NTCs were negative for Leptospira while ampliﬁcation of the IAC was
detected in all samples negative for Leptospira.
Amplicons from 10 of the false positive samples were sequenced;
none were identical to the 16S sequence of Leptospira spp. In 5 of the
samples, the sequence of the 55 bp between the primers was identical
to the 16S rRNA sequence of Peptostreptococcus stomatis and P. ana-
erobius. The P. anaerobius/stomatis sequence included 1 mismatch in
the forward primer, one mismatch in the probe and two mismatches
in the reverse primer. Sequences from the remaining 5 specimens
were identical to the rrs (16S) sequence of various uncultured bacteria.
In these sequences 0–2 mismatches with the probe sequence were
observed.
3.1.4. Determining sensitivity and speciﬁcity
When the real-time PCR assays were applied to BC from patients
suspected of leptospirosis (n=58) and the results were compared
with the reference methods, the sensitivity of the LipL32 real-time
PCR assay was 86% (n=7; 95% conﬁdence interval [CI]; 49% to 97%)
and the sensitivity of the 16S real-time PCR was 100% (n=7; 95% CI;65% to 100%)when at least two BC ﬂasks from each patientwere tested.
The corresponding speciﬁcity when applied to BCs was 100% (n=51;
95% CI; 88% to 100%) for LipL32 real-time PCR and 97% (n=51; 95%
CI; 83% to 99%) for 16S real-time PCR.
For urine samples from patients suspected of leptospirosis (n=58)
and controls (n=99), all of the four patients that were true positive by
one of the reference methods were also positive by both real-time PCR
assays. The speciﬁcity of LipL32 real-time PCR was 100% (n=153; 95%
CI; 97.6% to 100%), while the speciﬁcity of the 16S real-time PCR was
only 91.5% (n=153; 95% CI; 86.0% to 95.0%).
3.2. Evaluation with cultured bacterial strains
3.2.1. Bacterial isolates
The results of two real-time PCR assays applied to Leptospira spp. are
shown in Table 1. There was no cross-reactions in the two real-time
PCRs with puriﬁed DNA from T. pallidum, T. phagedenis and B. burgdorferi,
while a positive signal was observed in one of the duplicates of the 16S
real-time PCR when 10−2 of L. illini and dilution 10−3 of T. parva.
3.2.2. Determining the limit of detection
The LOD for the 16S real-time PCR was estimated to be 3 GEq/
5 μl template and for the LipL32 real-time PCR, 6 GEq/5 μl template
for L. interrogans serovar Icterohaemoragiae strain RGA could be
detected.
4. Discussion
In this study we present a novel LipL32 TaqMan® real-time PCR,
the ﬁrst reported Leptospira speciﬁc real-time PCR assay that has
been validated for both urine and blood specimens from humans.
Although urine is an important specimen for the diagnosis of leptospiro-
sis, none of the previously described Leptospira speciﬁc RT-PCR assays
have been validated for use with human urine (Ahmed et al., 2009;
Fearnley et al., 2008; Levett et al., 2005; Merien et al., 2005b;
Palaniappan et al., 2005; Smythe et al., 2002; Stoddard et al., 2009).
In the acute phase of leptospirosis, Leptospira disseminates to most
tissues where they multiply to a relatively high bacterial load (Segura
et al., 2005). We have previously shown that 7 out of 7 seropositive
cases of leptospirosis could be identiﬁed by PCR, when the 16S
real-time PCR was applied to two separate blood cultures, obtained be-
fore initiation of antimicrobial therapy and tested in duplicates
(Villumsen et al., 2010). In this study, we were able to ﬁnd leptospiral
DNA in 6 out of the 7 cases when the LipL32 real-time PCR was applied
to the same samples. The difference in the number of patients thatwere
positive by the two real-time PCRs is most likely explained by the small
difference in the LOD for the two assays. Previous studies presented a
sensitivity of 96% compared with culturing when PCR was applied to
one blood sample obtained before antimicrobial therapy (Slack et al.,
2007).We found a comparable sensitivity of 86% (95% conﬁdence inter-
val (CI); 49% to 97%) for the LipL32 real-time PCR and of 100% (95% CI;
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were tested in duplicate. When testing only one BC, the sensitivity was
lower for both real-time PCR assays compared with the previous ﬁnd-
ings in normal blood samples. This difference can be explained both
by the dilution of the blood that occurs in the blood culture ﬂask and
by the increased dilution of the corresponding DNA when this is
extracted from BCs compared with normal blood samples.
While Leptospira is cleared from most tissues after the ﬁrst days
of infection, it can colonize the lumen of the proximal convoluted
tubules of the kidneys within the following weeks. It is often stated
that Leptospira are only present in the urine from around the 7th
day of the disease (Yang et al., 2001). However, we diagnosed leptospi-
rosis by both real-time PCR assays in all of the four patients, where the
diagnosis was conﬁrmed by the reference methods, when the tested
urine samples that were obtained early in the course of the disease
and before initiation of antimicrobial therapy. Despite the low number
of patients, our results suggest that a high sensitivity can be obtained
by applying PCR to urine samples obtained early in the course of the dis-
ease, conﬁrming the few studies that have addressed this issue (Bal et
al., 1994; Brown et al., 1995; Saengjaruk et al., 2002).
While the clinical sensitivity of both LipL32 real-time PCR and 16S
real-time PCR was very high, we found an unacceptable high rate of
false-positive reactions when the 16S real-time PCR was used both
with blood cultures but especially with urine samples. Most PCR as-
says used in diagnostic laboratories have a clinical speciﬁcity very
close to 100%. We found that the speciﬁcity of the 16S real-time
PCR was only 91.5% and 97% in urine and blood cultures, respectively,
and even in an endemic country this would result in an unacceptable
low positive predictive value of the test. These ﬁndings, conﬁrm pre-
vious observations (Ganoza et al., 2010; Stoddard et al., 2009), and
suggest that the 16S real-time PCR can no longer be recommended
for primary diagnostic use. The LipL32 real-time PCR, in contrast,
did not produce false-positive reactions.
Unexpected cross-reactivity can to some extent be avoided by thor-
ough database studies and a few practical tests, if the assay is applied to
specimens like blood or spinal ﬂuid that under normal conditions are
sterile. However, assays targeting the rrs gene coding for 16S rRNA
which is conserved among many bacterial species are more prone to
unexpected cross-reactivity and extra care should be taken when vali-
dating these assays. In addition, as illustrated by our ﬁndings, in silico
validation is insufﬁcient if the assay is applied to urine and similar spec-
imens that contain a poorly characterized poly-microbial ﬂora. Thus, we
emphasize the need of validating all diagnostic PCR assays on a broad
selection of relevant samples.
Our ﬁndings suggest that all relevant Leptospira spp. are detected by
LipL32 real-time PCR with high sensitivity close to the theoretical LOD
of 3 GEq/assay. The observed difference in the LOD between the two
real-time PCR assays is expected since the lipl32 gene is present in one
copy on the genome of L. interrogans (Haake et al., 2000b), while
there are two copies of the rrs gene (Fukunaga and Mifuchi, 1989). Of
the classiﬁed pathogenic species, only Leptospira genomospecies 1, a can-
didate species has been isolated from a frog, was missed by the LipL32
real-time PCR (Brenner et al., 1999). Of the intermediate pathogenic
species Leptospira broomii was detected by both assays. However, this
species has been isolated previously from hospitalized patients
(Arzouni et al., 2002; Levett et al., 2006; Petersen et al., 2001). As orig-
inally reported, the 16S real-time PCR was able to detect all pathogenic,
intermediate pathogenic Leptospira spp. tested, as well as the sapro-
phytic L. meyeri (Smythe et al., 2002). These species were detected by
the 16S real-time PCR at a low LOD except for L. genomospecies 3 in
which there is only low homology between primers and the target se-
quence. The clinical signiﬁcance of the difference in species detected
by LipL32 real-time PCR and 16S real-time PCR is questionable since
the human pathogenicity of the species missed by LipL32 is not fully
elucidated. The intermediate pathogenic Leptospira fainei has only
been isolated from pigs (Perolat et al., 1998), Leptospira inadai onlyonce from a human skin biopsy (Schmid et al., 1986) and the pathoge-
nicity of L. meyeri is disputed (Postic et al., 2000).
The strength of this study is that a thorough validation of the speci-
ﬁcity of both diagnostic assays was done when these were applied to
both urine and blood samples fromhumans. However, as human chron-
ic renal carriers have been described in Peru (Ganoza et al., 2010), the
clinical speciﬁcity would have to be reassessed at least once in an en-
demic population. Performing the study in an endemic population,
would further ease inclusion of a larger number of patients and, there-
by, allow a more exact estimate of the clinical sensitivity of the assays.
The concentration of Leptospira in the DNA extract of the clinical sam-
ples was in most cases close to the theoretical LOD of the real-time
PCRassays. This suggests that future research in optimizing the sensitiv-
ity of these assays should focus on increasing the amount of the target
DNA in the assays for example by concentrating the Leptospira spp.
DNA in the template as we did in the DNA extraction from urine sam-
ples. Another approach would be to increase the amount of template
DNA used as it was done in some of the early Leptospira speciﬁc conven-
tional PCR assays (Bal et al., 1994; Gravekamp et al., 1993). In these as-
says the amount of template was eighth times the volume used in the
assays described in the present study. Even though such an approach
is more likely to cause problemswith inhibition of the assays, it is likely
to be one of the explanations for the relatively high clinical sensitivity
observed in these early assays.
5. Conclusions
We validated the ﬁrst Leptospira speciﬁc real-time PCR, LipL32
real-time PCR for application on both urine and blood samples from
humans. Our evaluation suggests that most cases of leptospirosis can
be diagnosed by the LipL32 real-time PCR if applied to either one
urine sample or at least two blood cultures taken before antimicrobial
therapy is initiated. Re-evaluating the previously described 16S
real-time PCR with the same samples, we found that both the clinical
and the analytical sensitivity were slightly better for this assay com-
pared with the LipL32 real-time PCR. However, the 16S real-time PCR
had a high rate of false-positive reactions with some other bacteria
and can, therefore, not be recommended for clinical diagnostics. In con-
trast, no false positive reactions were observed in any of the samples
that were tested by the LipL32 real-time PCR.
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Appendix A
A.1. Genbank number of the lipl32 gene sequences used in the design of
the primers and probe of the LipL32 qPCR
AB094433, AB094434, AB094435, AB094436, AB094437,
AE010300, AF121192, AF181553, AF181554, AF181555, AF181556,
AF245281, AJ580493, AR174015, AY423075, AY442332, AY461893,
AY461894, AY461895, AY461896, AY461897, AY461898, AY461899,
AY461900, AY461901, AY461902, AY461903, AY461904, AY461905,
AY461906, AY461907, AY461908, AY461909, AY461910, AY461911,
AY461912, AY461913, AY461914, AY461915, AY461916, AY461917,
AY461918, AY461919, AY461920, AY461921, AY461922, AY461923,
AY461924, AY461925, AY461926, AY461928, AY461929, AY461930,
AY568679, AY568680, AY609321,AY609322, AY609323, AY609324,
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AY609331, AY609332, AY609333, AY776292, AY776293, CP000348,
CP000350, DQ149595, DQ092412, DQ286415 DQ286416, DQ286417,
DQ286418, DQ461927, NC_004342, NC_008508, and NC_008510.References
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IAC: Internal ampliﬁcation control
LOD: Limit of detection
LOQ: Limit-of-quantiﬁcation
MAT: Microscopic agglutination test
NTC: No-template control
PCR: Polymerase chain reaction
